Enfermedades por micobacterias no tuberculosas en España: tratamiento y evolución

Villanueva-Montes, Manuel Ángel; Álvarez Navascués, Fernando; Gullón Blanco, José Antonio; Rodrigo Sanz, Teresa; Medina Gallardo, Juan Francisco; Caminero Luna, José Antonio; García-García, José María.
Arch. bronconeumol. (Ed. impr.) ; 58(5): 457-460, Mayo 2022. tab
Artículo en Español | IBECS (España) | ID: ibc-206616

Documentos relacionados

  1. [Two severe cases of disseminated cutaneous nontuberculous mycobacteriosis due to Mycobacterium haemophilum].
  2. Inactivation of nontuberculous mycobacteria by gaseous ozone treatment.
  3. [Translated article] Non-Tuberculous Mycobacterial Diseases in Spain: Treatment and Evolution
  4. Non-tuberculous mycobacteriosis of the liver responsive to empiric therapy.
  5. Why do we use 100 mg of clofazimine in TB and NTM treatment?
  6. Anti-Interferon Gamma Autoantibody and Disseminated Nontuberculous Mycobacteria Infection: What Should Be Done to Improve Its Clinical Outcome?
  7. Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti-Interferon-γ Autoantibodies.
  8. The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria.
  9. Nontuberculous mycobacterial disease: a case report-based review.
  10. Mycobacterium marinum infection of the wrist.